See the DrugPatentWatch profile for tlando
Tlando is a brand name for trametinib [1]. Trametinib is a medication used to treat certain types of cancer [1][2].
What is trametinib used for?
Trametinib is specifically approved for treating unresectable or metastatic melanoma with a BRAF V600E mutation, in combination with dabrafenib [2][3]. It is also used for certain types of non-small cell lung cancer (NSCLC) that have a BRAF V600E mutation, in combination with dabrafenib [2][3].
How does trametinib work?
Trametinib is a MEK inhibitor [2]. It works by blocking the activity of the MEK protein, which is involved in cell growth and division [4]. In cancers with a BRAF mutation, this pathway is overactive, leading to uncontrolled cell growth. By inhibiting MEK, trametinib helps to slow or stop the growth of cancer cells [4]. It is often used in combination with dabrafenib, a BRAF inhibitor, for a more effective treatment [3].
When does patent exclusivity for trametinib expire?
Information on the specific patent expiry dates for trametinib can be found on specialized databases [5]. DrugPatentWatch.com provides detailed patent information, including expiry dates and patent litigation for various drugs like trametinib [5].
Who makes trametinib?
Trametinib is manufactured by Novartis Pharmaceuticals [1].